Hookipa Pharma Inc. (HOOK) NASDAQ

$0.71 (0.01) (-1.17%)

Market Cap: $69.56M

As of 03/28/24 04:00 PM EDT. Market closed.

(HOOK)

Hookipa Pharma Inc. (HOOK)
NASDAQ

$0.71
(0.01) (-1.17%)

Market Cap: $69.56M

As of 03/28/24 04:00 PM EDT. Market closed.

Add to Portfolio

hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent ... read more

hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a read less

COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Full Time Employees
133
CEO Compensation (Base)
$361,600
Address
.
PRICE CHART FOR HOOKIPA PHARMA INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$0.73
Previous Close
$0.72
Days Range
$0.71 - $0.73
52 week range
$0.41 - $2.05
Volume
376,099
Avg. Volume (30 days)
500,189
Market Cap
$69.56M
Dividend Yield
-
P/E
(0.85)
Shares Outstanding
96,550,590
Open
$0.73
Previous Close
$0.72
Days Range
$0.71 - $0.73
52 week range
$0.41 - $2.05
Volume
376,099
Avg. Volume (30 days)
500,189
Market Cap
$69.56M
Dividend Yield
-
P/E
(0.85)
Shares Outstanding
96,550,590
FINANCIAL STATEMENTS FOR HOOKIPA PHARMA INC
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR HOOKIPA PHARMA INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Kandera ReinhardChief Financial OfficerAug 21, 2023 Buy$0.737,0005,07543,092Aug 22, 2023, 04:01 PM
Kandera ReinhardChief Financial OfficerAug 16, 2023 Buy$0.718,0005,71236,092Aug 17, 2023, 04:05 PM
Aldag JornChief Executive OfficerJul 11, 2023 Buy$0.835,0004,14271,952Jul 11, 2023, 06:21 PM
Aldag JornChief Executive OfficerJul 07, 2023 Buy$0.815,0004,05066,952Jul 11, 2023, 06:21 PM
Aldag JornChief Executive OfficerJul 05, 2023 Buy$0.895,0004,45061,952Jul 07, 2023, 05:06 PM
Aldag JornChief Executive OfficerJul 03, 2023 Buy$0.895,0004,45556,952Jul 05, 2023, 07:37 PM
Kandera ReinhardChief Financial OfficerJun 30, 2023 Buy$0.8812,00010,56028,092Jul 03, 2023, 04:06 PM
Orlinger KlausExecutive VP, ResearchFeb 01, 2022 Option Exercise$3.009,18827,56410,404Feb 01, 2022, 08:52 PM
Baker Christine D.Chief Business OfficerFeb 01, 2022 Option Exercise$3.0013,65840,97416,158Feb 01, 2022, 08:50 PM
Necina RomanChief Technology OfficerFeb 01, 2022 Option Exercise$3.0012,89238,67614,876Feb 01, 2022, 08:50 PM
Matushansky IgorChief Medical OfficerFeb 01, 2022 Option Exercise$3.0014,93344,799100,240Feb 01, 2022, 08:49 PM
Kandera ReinhardChief Financial OfficerFeb 01, 2022 Option Exercise$3.0014,05642,16816,092Feb 01, 2022, 08:48 PM
Aldag JornChief Executive OfficerFeb 01, 2022 Option Exercise$3.0047,824143,47251,952Feb 01, 2022, 08:44 PM
Matushansky IgorChief Medical OfficerDec 21, 2021 Option Exercise$0.1022,8532,28591,544Jan 12, 2022, 10:07 AM
Matushansky IgorChief Medical OfficerDec 21, 2021 Sale$2.4914,94937,22385,307Jan 12, 2022, 10:07 AM
SOFINNOVA CAPITAL VI FCPR10% OwnerApr 21, 2021 Sale$11.60328,6203,812,3863,177,574Apr 23, 2021, 04:30 PM
SOFINNOVA CAPITAL VI FCPR10% OwnerMar 29, 2021 Sale$13.6736,829503,5703,506,194Mar 31, 2021, 04:06 PM
SOFINNOVA CAPITAL VI FCPR10% OwnerMar 26, 2021 Sale$13.6935,171481,6423,543,023Mar 31, 2021, 06:01 AM
SOFINNOVA CAPITAL VI FCPR10% OwnerMar 25, 2021 Sale$13.1228,546374,5693,578,194Mar 29, 2021, 04:01 PM
SOFINNOVA CAPITAL VI FCPR10% OwnerMar 24, 2021 Sale$13.7052,690721,6163,606,740Mar 26, 2021, 07:12 PM
SOFINNOVA CAPITAL VI FCPR10% OwnerMar 23, 2021 Sale$13.9140,000556,4763,659,430Mar 25, 2021, 06:13 PM
SOFINNOVA CAPITAL VI FCPR10% OwnerMar 22, 2021 Sale$14.5440,534589,2633,699,430Mar 24, 2021, 06:16 PM
SOFINNOVA CAPITAL VI FCPR10% OwnerMar 19, 2021 Sale$14.60166,2302,427,7393,739,964Mar 23, 2021, 04:31 PM
Matushansky IgorChief Medical OfficerDec 17, 2020 Option Exercise$0.1048,9884,89993,881Dec 18, 2020, 04:04 PM
Matushansky IgorChief Medical OfficerDec 16, 2020 Option Exercise$0.106406456,774Dec 18, 2020, 04:04 PM
Matushansky IgorChief Medical OfficerDec 17, 2020 Sale$11.7427,979328,34377,403Dec 18, 2020, 04:04 PM
Matushansky IgorChief Medical OfficerDec 16, 2020 Sale$11.703804,44656,394Dec 18, 2020, 04:04 PM
SOFINNOVA CAPITAL VI FCPR10% OwnerOct 02, 2020 Sale$10.003003,0003,906,194Oct 06, 2020, 04:01 PM
SOFINNOVA CAPITAL VI FCPR10% OwnerSep 15, 2020 Sale$12.6141,597524,4773,915,755Sep 17, 2020, 04:02 PM
SOFINNOVA CAPITAL VI FCPR10% OwnerJun 29, 2020 Sale$11.783,28038,6283,960,574Jul 24, 2020, 05:07 PM
SOFINNOVA CAPITAL VI FCPR10% OwnerJun 29, 2020 Sale$11.783,28038,6283,960,574Jul 22, 2020, 04:03 PM
SOFINNOVA CAPITAL VI FCPR10% OwnerJul 20, 2020 Sale$11.9412,483149,1023,948,091Jul 22, 2020, 04:03 PM
SOFINNOVA CAPITAL VI FCPR10% OwnerJun 29, 2020 Sale$11.783,28038,6283,960,574Jul 01, 2020, 04:16 PM
Matushansky IgorChief Medical OfficerJan 29, 2020 Sale$12.735,50069,99253,398Jan 31, 2020, 04:01 PM
Lilja AndersSr. VP, Technical DevelopmentJan 23, 2020 Option Exercise$0.1011,6431,1647,568Jan 27, 2020, 04:52 PM
Lilja AndersSr. VP, Technical DevelopmentJan 23, 2020 Sale$12.5911,643146,5330Jan 27, 2020, 04:52 PM
Orlinger KlausSr. VP, ResearchJan 21, 2020 Option Exercise$0.106,7896796,789Jan 21, 2020, 04:44 PM
Orlinger KlausSr. VP, ResearchJan 16, 2020 Option Exercise$0.101,7111711,711Jan 21, 2020, 04:44 PM
Orlinger KlausSr. VP, ResearchJan 21, 2020 Sale$12.026,78981,5920Jan 21, 2020, 04:44 PM
Orlinger KlausSr. VP, ResearchJan 16, 2020 Sale$11.561,71119,7810Jan 21, 2020, 04:44 PM
Orlinger KlausSr. VP, ResearchJan 14, 2020 Option Exercise$0.108,5008508,500Jan 16, 2020, 04:06 PM
Orlinger KlausSr. VP, ResearchJan 14, 2020 Sale$11.308,50096,0530Jan 16, 2020, 04:06 PM
Matushansky IgorChief Medical OfficerDec 19, 2019 Option Exercise$0.1025,8912,58969,302Dec 23, 2019, 08:30 AM
Matushansky IgorChief Medical OfficerDec 19, 2019 Sale$9.9310,404103,31258,898Dec 23, 2019, 08:30 AM
Matushansky IgorChief Medical OfficerDec 17, 2019 Option Exercise$0.1026,3122,63154,895Dec 19, 2019, 04:03 PM
Matushansky IgorChief Medical OfficerDec 17, 2019 Sale$7.8711,48490,37943,411Dec 19, 2019, 04:03 PM
Forbion Capital Fund II Cooperatief U.A.10% OwnerApr 23, 2019 Buy$14.0053,571749,9942,494,173Apr 25, 2019, 04:15 PM
SOFINNOVA CAPITAL VI FCPR10% OwnerApr 23, 2019 Buy$14.00357,1424,999,9883,963,854Apr 25, 2019, 04:15 PM
BAKER BROS. ADVISORS LPFormer 10% ownerApr 23, 2019 Buy$14.00892,85712,499,998820,729Apr 23, 2019, 04:54 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Kandera ReinhardChief Financial Officer08/21/20235,075
Kandera ReinhardChief Financial Officer08/16/20235,712
Aldag JornChief Executive Officer07/11/20234,142
Aldag JornChief Executive Officer07/07/20234,050
Aldag JornChief Executive Officer07/05/20234,450
Aldag JornChief Executive Officer07/03/20234,455
Kandera ReinhardChief Financial Officer06/30/202310,560
Orlinger KlausExecutive VP, Research02/01/202227,564
Baker Christine D.Chief Business Officer02/01/202240,974
Necina RomanChief Technology Officer02/01/202238,676
Matushansky IgorChief Medical Officer02/01/202244,799
Kandera ReinhardChief Financial Officer02/01/202242,168
Aldag JornChief Executive Officer02/01/2022143,472
Matushansky IgorChief Medical Officer12/21/20212,285
Matushansky IgorChief Medical Officer12/21/202137,223
SOFINNOVA CAPITAL VI FCPR10% Owner04/21/20213,812,386
SOFINNOVA CAPITAL VI FCPR10% Owner03/29/2021503,570
SOFINNOVA CAPITAL VI FCPR10% Owner03/26/2021481,642
SOFINNOVA CAPITAL VI FCPR10% Owner03/25/2021374,569
SOFINNOVA CAPITAL VI FCPR10% Owner03/24/2021721,616
SOFINNOVA CAPITAL VI FCPR10% Owner03/23/2021556,476
SOFINNOVA CAPITAL VI FCPR10% Owner03/22/2021589,263
SOFINNOVA CAPITAL VI FCPR10% Owner03/19/20212,427,739
Matushansky IgorChief Medical Officer12/17/20204,899
Matushansky IgorChief Medical Officer12/16/202064
Matushansky IgorChief Medical Officer12/17/2020328,343
Matushansky IgorChief Medical Officer12/16/20204,446
SOFINNOVA CAPITAL VI FCPR10% Owner10/02/20203,000
SOFINNOVA CAPITAL VI FCPR10% Owner09/15/2020524,477
SOFINNOVA CAPITAL VI FCPR10% Owner06/29/202038,628
SOFINNOVA CAPITAL VI FCPR10% Owner06/29/202038,628
SOFINNOVA CAPITAL VI FCPR10% Owner07/20/2020149,102
SOFINNOVA CAPITAL VI FCPR10% Owner06/29/202038,628
Matushansky IgorChief Medical Officer01/29/202069,992
Lilja AndersSr. VP, Technical Development01/23/20201,164
Lilja AndersSr. VP, Technical Development01/23/2020146,533
Orlinger KlausSr. VP, Research01/21/2020679
Orlinger KlausSr. VP, Research01/16/2020171
Orlinger KlausSr. VP, Research01/21/202081,592
Orlinger KlausSr. VP, Research01/16/202019,781
Orlinger KlausSr. VP, Research01/14/2020850
Orlinger KlausSr. VP, Research01/14/202096,053
Matushansky IgorChief Medical Officer12/19/20192,589
Matushansky IgorChief Medical Officer12/19/2019103,312
Matushansky IgorChief Medical Officer12/17/20192,631
Matushansky IgorChief Medical Officer12/17/201990,379
Forbion Capital Fund II Cooperatief U.A.10% Owner04/23/2019749,994
SOFINNOVA CAPITAL VI FCPR10% Owner04/23/20194,999,988
BAKER BROS. ADVISORS LPFormer 10% owner04/23/201912,499,998
Load More Insider Transactions
FUNDS WITH A POSITION IN HOOKIPA PHARMA INC
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
BAKER BROS. ADVISORS LP8,128,1510.07%0.78%Other
GEODE CAPITAL MANAGEMENT, LLC585,6070.00005%9.85%Other
RENAISSANCE TECHNOLOGIES LLC188,6460.00024%-66.05%Other
BLACKROCK INC.294,2720.00001%-0.33%Other
CHANGE IN SHARES OUTSTANDING FOR HOOKIPA PHARMA INC
STOCK BUYBACKS FOR HOOKIPA PHARMA INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
12/31/2023
09/30/2023
0%
1Q
12/31/2023
09/30/2022
53.46%
5Q
12/31/2023
06/30/2022
53.49%
6Q
12/31/2023
03/31/2022
53.51%
7Q
Load More

Period of Report: 12/31/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
09/30/2023
0%
1Q
09/30/2022
53.46%
5Q
06/30/2022
53.49%
6Q
03/31/2022
53.51%
7Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR HOOKIPA PHARMA INC
LOADING...